Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1977 1
1980 2
1982 1
1984 1
1985 2
1986 1
1987 3
1988 1
1989 2
1990 2
1991 2
1992 2
1993 1
1994 3
1995 1
1996 4
1997 5
1998 4
1999 2
2000 5
2001 5
2002 4
2003 5
2004 5
2005 4
2006 2
2007 5
2008 3
2009 4
2010 4
2011 8
2012 8
2013 6
2014 7
2015 11
2016 6
2017 3
2018 11
2019 10
2020 2
2021 6
2022 3
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Aplastic Anemia"
Page 1
Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment.
Georges GE, Doney K, Storb R. Georges GE, et al. Blood Adv. 2018 Aug 14;2(15):2020-2028. doi: 10.1182/bloodadvances.2018021162. Blood Adv. 2018. PMID: 30108110 Free PMC article. Review.
Treatment of severe aplastic anemia has improved significantly over the past 4 decades. ...Implementation of this first-line treatment strategy will provide patients with severe aplastic anemia the best chance of long-term disease-free survival....
Treatment of severe aplastic anemia has improved significantly over the past 4 decades. ...Implementation of this first-line t …
Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review.
Devalet B, Mullier F, Chatelain B, Dogné JM, Chatelain C. Devalet B, et al. Eur J Haematol. 2015 Sep;95(3):190-8. doi: 10.1111/ejh.12543. Epub 2015 Mar 26. Eur J Haematol. 2015. PMID: 25753400 Review.
Patients experience intravascular hemolysis, smooth muscle dystonia, renal failure, arterial and pulmonary hypertension, recurrent infectious diseases and an increased risk of notably dreadful thrombotic complications. ...Efforts have been recently performed to improve the …
Patients experience intravascular hemolysis, smooth muscle dystonia, renal failure, arterial and pulmonary hypertension, recurrent in …
Temozolomide-related hematologic toxicity.
Scaringi C, De Sanctis V, Minniti G, Enrici RM. Scaringi C, et al. Onkologie. 2013;36(7-8):444-9. doi: 10.1159/000353752. Epub 2013 Jul 8. Onkologie. 2013. PMID: 23921765 Review.
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with significant survival benefit. ...However severe hematologic adverse events (HAEs), including myelodysplastic syndrome and aplastic anemia …
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with signific …
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU; AVANOVA investigators. Mirza MR, et al. Lancet Oncol. 2019 Oct;20(10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. Epub 2019 Aug 29. Lancet Oncol. 2019. PMID: 31474354 Clinical Trial.
AVANOVA2 compared niraparib and bevacizumab versus niraparib alone as definitive treatment for platinum-sensitive recurrent ovarian cancer. METHODS: This open-label, randomised, phase 2, superiority trial in 15 university hospitals in Denmark, Sweden, Finland, Norway, and …
AVANOVA2 compared niraparib and bevacizumab versus niraparib alone as definitive treatment for platinum-sensitive recurrent ovarian c …
Acquired aplastic anemia.
Young NS. Young NS. Ann Intern Med. 2002 Apr 2;136(7):534-46. doi: 10.7326/0003-4819-136-7-200204020-00011. Ann Intern Med. 2002. PMID: 11926789 Free article. Review.
In aplastic anemia, hematopoiesis fails: Blood cell counts are extremely low, and the bone marrow appears empty. ...Aplastic anemia can be effectively treated by stem-cell transplantation or immunosuppressive therapy. ...
In aplastic anemia, hematopoiesis fails: Blood cell counts are extremely low, and the bone marrow appears empty. ...Aplasti …
Molecular pathogenesis of acquired aplastic anemia.
Boddu PC, Kadia TM. Boddu PC, et al. Eur J Haematol. 2019 Feb;102(2):103-110. doi: 10.1111/ejh.13182. Epub 2018 Dec 18. Eur J Haematol. 2019. PMID: 30380171 Review.
The application of next-generation sequencing (NGS) has enhanced our understanding of the genetic landscape in acquired aplastic anemia (AA). Parallel progress has been in addressing aspects underlying immune dysregulation in disease pathogenesis. ...The detection o …
The application of next-generation sequencing (NGS) has enhanced our understanding of the genetic landscape in acquired aplastic a …
Hepatitis-associated aplastic anemia.
Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS. Brown KE, et al. N Engl J Med. 1997 Apr 10;336(15):1059-64. doi: 10.1056/NEJM199704103361504. N Engl J Med. 1997. PMID: 9091802 Free article.
BACKGROUND: Hepatitis-associated aplastic anemia is a variant of aplastic anemia in which aplastic anemia follows an acute attack of hepatitis. ...All patients were treated with antithymocyte globulin and cyclosporine. RESULTS: Ten patien …
BACKGROUND: Hepatitis-associated aplastic anemia is a variant of aplastic anemia in which aplastic ane …
Recurrent Polyuria.
Arora N, Durvasula R. Arora N, et al. Am J Kidney Dis. 2018 Nov;72(5):A17-A19. doi: 10.1053/j.ajkd.2018.07.006. Am J Kidney Dis. 2018. PMID: 30343734 No abstract available.
Neonatal manifestations of inherited bone marrow failure syndromes.
Khincha PP, Savage SA. Khincha PP, et al. Semin Fetal Neonatal Med. 2016 Feb;21(1):57-65. doi: 10.1016/j.siny.2015.12.003. Epub 2015 Dec 24. Semin Fetal Neonatal Med. 2016. PMID: 26724991 Free PMC article. Review.
The inherited bone marrow failure syndromes (IBMFS) are a rare yet clinically important cause of neonatal hematological and non-hematological manifestations. Many of these syndromes, such as Fanconi anemia, dyskeratosis congenita and Diamond-Blackfan anemia, confer …
The inherited bone marrow failure syndromes (IBMFS) are a rare yet clinically important cause of neonatal hematological and non-hematologica …
Revisiting acquired aplastic anaemia: current concepts in diagnosis and management.
Clucas DB, Fox LC, Wood EM, Hong FS, Gibson J, Bajel A, Szer J, Blombery P, McQuilten ZK, Hiwase D, Firkin F, Cole-Sinclair MF; Australian Aplastic Anaemia Registry Steering Committee. Clucas DB, et al. Intern Med J. 2019 Feb;49(2):152-159. doi: 10.1111/imj.14140. Intern Med J. 2019. PMID: 30324755 Review.
Acquired aplastic anaemia is a rare, serious, immunologically mediated bone marrow failure syndrome, characterised by marrow hypoplasia of varying severity and significant pancytopenia. ...
Acquired aplastic anaemia is a rare, serious, immunologically mediated bone marrow failure syndrome, characterised by marrow h …
164 results